<unk>  is indicated for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. It may be administered as a continuous subcutaneous infusion or continuous intravenous infusion; however, because of the risks associated with chronic indwelling central venous catheters, including serious blood stream infections, continuous intravenous infusion should be reserved for patients who are intolerant of the subcutaneous route, or in whom these risks are considered warranted. This medication is also available in inhaled and tablet forms. In patients with pulmonary arterial hypertension requiring transition from epoprostenol sodium (Flolan),<unk>  is indicated to diminish the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition.<unk>  therapy may be effective in treating Degos disease.
Treprostinil
Tadalafil
Oxybutynin
Avanafil
Vardenafil
Udenafil
Finasteride
Acebutolol